Gus Cairns

Gus joined NAM's editorial team in 2009 and previously edited HIV Treatment Update and Preventing HIV. Twitter: @guscairns

PrEP science

More evidence that PrEP works as well for women

Injectable & long-acting PrEP

Why is the roll-out of injectable PrEP taking so long?

PrEP policies & guidelines

Should event-driven PrEP be an option for women?

Resistance

The cornerstone of HIV treatment may be losing some of its power: will dolutegravir resistance become a problem?

PrEP

Six-country African PrEP study achieves high levels of persistence and good adherence in young women

New & experimental HIV treatments

If one antibody won’t work, how about three? Or three in one?

Sexually transmitted infections prevention

Full analysis of French STI study dashes hopes for a gonorrhoea vaccine

HIV vaccine & cure research

Diversity and equity in HIV cure research

HIV vaccine & cure research

Ethics in cure research

The search for a cure

Cases of HIV cure

PrEP science

Oral PrEP can work just as well for women as men, modelling studies conclude

The search for a cure

Why is HIV hard to cure?

TB transmission & prevention

Tuberculosis still much more common in people with HIV in high-income settings

The search for a cure

The search for an HIV cure

Global health targets

“Zero chance” of meeting goal of ending HIV transmission among UK gay and bisexual men by 2030

Mental & emotional health problems

Suicide rate has fallen in Catalans with HIV – but is still higher than in the general population

PrEP science

PrEP and sexually transmitted infections

Access to healthcare

HIV services in Ukraine resilient but starting to feel the strain